Overview
Cognito Therapeutics has raised $105 million in a Series C round to advance its sensory neurostimulation platform for Alzheimer's disease. The company's approach uses precisely calibrated 40Hz light and sound stimulation to entrain gamma oscillations in the brain — neural rhythms that are disrupted in Alzheimer's and associated with memory and cognitive function.
The Science
The technology is based on groundbreaking research from MIT's Tsai and Bhatt Labs showing that 40Hz sensory stimulation can reduce amyloid and tau pathology, decrease neuroinflammation, and improve cognitive function in mouse models of Alzheimer's. Cognito has translated this into a wearable device that delivers the therapy at home.
Clinical Data
The company's Phase 2 clinical trial demonstrated that daily 40Hz stimulation slowed brain atrophy and functional decline in Alzheimer's patients compared to sham treatment over 6 months. The therapy showed a favorable safety profile with high patient compliance — critical for a treatment requiring daily use.
Why It Matters
With Alzheimer's drug development historically plagued by a 99% failure rate, a non-invasive, non-pharmacological approach that can be administered at home represents an entirely different paradigm. If Phase 3 confirms efficacy, it could become the first neurostimulation therapy approved for Alzheimer's.
